A PhaseⅡ of Injection for Recombinant Human Tissue Plasminogen Kinase Derivative in Treatment of Acute Ischemic Stroke.
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 180 participants.
Also called NCT04028518
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 180 participants
- Sponsor
- Registry
-
NCT04028518
-
- Other papers using this trial's data
- Safety and Efficacy of Reteplase Versus Alteplase for Acute Ischemic Stroke: A Phase 2 Randomized Controlled Trial
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT04028518. Randomized; no masking; primary purpose treatment. Start 2019-07-20 (anticipated); primary completion 2020-10-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A PhaseⅡ of Injection for Recombinant Human Tissue Plasminogen Kinase Derivative in Treatment of Acute Ischemic Stroke.
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- r-PA
- Intervention (Drug)
- r-PA
- Intervention (Drug)
- Alteplase for Injection
- Lead sponsor
- Angde Biotech Pharmaceutical Co., Ltd.
- Collaborator
- Beijing Tiantan Hospital
Record details
- Record id
cardio:ct-nct04028518- Content hash
1757bc71efd5c3cc0155f33138890d713e8a9c0d732c3444fd0f7a2b6ddae4fc